Firering Strategic Minerals: From explorer to producer. Watch the video here.
It's there now :)
I topsliced some ITX at higher prices (sadly not 18p!), but have bought them all back at sub 4p.
I am very confident in the ITX products, prospects and board in the medium-term and long-term. It's the short-term volatility that will allow us PIs to get in at a good price for the next phase of the journey.
First post on ITX? Seems like you haven't been here long. Try doing some research and you will understand more.
A re-branding for ULS and a change of name.
Smoove is probably easier to market than ULS technology (a la Belvoir!), but I feel silly saying it. I'm sure it won't stop Kestrel from continuing to accumulate.
Is a change of ticker coming?
I'm with x-o (aka Jarvis). So it's not just my provider :(
I didn't receive my DRV divi in my account yesterday. How about anyone else?
Another director purchase: Andrew Ross, spending £90,000 to buy another 15,000 shares at 590p.
I don't think it's a coincidence that it took OOL 15 mins to report his sale on here, and that 15 mins is the lag time before sales appear on the LSE Share Trades section.
It's almost as if he waited for a trade to appear and then declared that it was his...
...but I'm sure that couldn't be, and I'm sure OOL is a fine upstanding deramper, not one of those desperate posters who would make things up to bash the share on an online message board :)
Ouch. This is pretty painful, but it sounds like they're clearing some dead wood and this should be the bottom. No point selling down here.
Another RNS, after hours this time: 8,000 more shares for the Kestrel Krew.
Continuing to up their stakes at these relatively low levels.
As predicted, SO didn't stop selling, and the Nemean Funds are going too.
When he is finally out, this will properly re-rate.
All the shorters who just opened new positions are now guaranteed buyers for the next leg up!
Basically, his 0% reponse rate comes from the reporting that tumours stabilised for 6 months.
He says that "Yet, in a field typically defined by evidence that interventions shrink tumors and prolong lives, success based on stable disease in four patients could be seen as slight."
He is ignoring the fact that the patients enrolled in this study has solid progressing tumours, and going purely by his own, unwarranted, metric of what should happen to count as a success.
Stablising a patient at this stage of cancer progression is remarkable, and a novel use of LBPs. Which is what his article should have focussed on. The dufus.
I am unsure where he gets the 0% response rate from.
His article is very "light" on any actual scientific evaluation of the data. Even for a popular science blog, it's slight.
My guess is that this freelance guy gets paid for pumping out "content" on this website and he only used half his ass to generate this article.
Please ask him if he could explain in more detail why he chooses to interpret the data in this way, because the data does not seem to correlate with his interpretation, and his interpretation itself is unclear.
My guess is that he won't really be able to defend his position because he doesn't really care.
That's just it, he's not buying to move the needle or to send a message.
He is trying NOT to move the share price. This is buying as an investor, not a board member.
Think about this: Someone with a £20m portfolio wouldn't bother buying repeated £10k chunks for a 5% profit. But they would for a 50% profit.